IN8bio (INAB)

Executive Summary

IN8bio is a clinical-stage biopharmaceutical company pioneering gamma-delta (γδ) T cell therapies for solid and hematological malignancies. Leveraging its proprietary DeltEx™ platform, the company engineers allogeneic, autologous, and genetically modified γδ T cells designed to target tumors with low mutational burden, such as glioblastoma (GBM) and leukemias following bone marrow transplantation. IN8bio's lead program, INB-200, is in a Phase 2 trial for newly diagnosed GBM, where it has shown encouraging preliminary safety and efficacy data, including extended progression-free survival. Additionally, the company is advancing INB-100 in a Phase 1/2 study for leukemia patients undergoing haploidentical transplant, with initial results demonstrating sustained donor engraftment and potential reduction in relapse. As a clinical-stage company with a novel immunotherapy approach, IN8bio represents a compelling opportunity in the cell therapy space, though it remains early-stage with significant execution risk and a modest valuation of approximately $15.8 million.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 GBM Data Update40% success
• H1 2027Phase 1/2 Leukemia Transplant Study Interim Results50% success
• Q2 2026Potential Strategic Partnership or Financing60% success